5 November 2012
Immunocore Limited today announced that is has been awarded a grant totalling £2.4 million from the government-backed Biomedical Catalyst fund.
Immunocore will use the award to take forward the clinical development of a new targeted therapy for the treatment of prostate cancer. Immunocore has developed a new class of biologic drug which recognise changes within cells so can be used to treat diseases – such as prostate cancer – that are not currently amenable to targeted biological therapies.
Please click on the link below to download the full Press Release:
Immunocore announces award of £2.4m from Biomedical Catalyst Fund
